Safety of human papillomavirus vaccines: an updated review
A Phillips, C Patel, A Pillsbury, J Brotherton… - Drug safety, 2018 - Springer
Human papillomavirus (HPV) vaccines are now included in immunisation programmes in 71
countries. Unfortunately, uptake has been impacted in some countries by reduced …
countries. Unfortunately, uptake has been impacted in some countries by reduced …
[HTML][HTML] Safety of human papillomavirus vaccines: a review
KK Macartney, C Chiu, M Georgousakis… - Drug safety, 2013 - Springer
Vaccination to prevent human papillomavirus (HPV)-related infection leading to cancer,
particularly cervical cancer, is a major public health breakthrough. There are currently two …
particularly cervical cancer, is a major public health breakthrough. There are currently two …
Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in …
L Arnheim-Dahlström, B Pasternak, H Svanström… - Bmj, 2013 - bmj.com
Objective To assess the risk of serious adverse events after vaccination of adolescent girls
with quadrivalent human papillomavirus (qHPV) vaccine. Design Register based cohort …
with quadrivalent human papillomavirus (qHPV) vaccine. Design Register based cohort …
The short term safety of COVID‐19 vaccines in Australia: AusVaxSafety active surveillance, February–August 2021
Objective To assess the short term safety of the COVID‐19 vaccines Comirnaty (Pfizer–
BioNTech BNT162b2) and Vaxzevria (AstraZeneca ChAdOx1) in Australia. Design …
BioNTech BNT162b2) and Vaxzevria (AstraZeneca ChAdOx1) in Australia. Design …
Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
J Gee, C Weinbaum, L Sukumaran… - Human vaccines & …, 2016 - Taylor & Francis
Quadrivalent human papillomavirus (4vHPV) vaccine was licensed for use in the United
States in 2006 and through 2015 was the predominate HPV vaccine used. With the …
States in 2006 and through 2015 was the predominate HPV vaccine used. With the …
[HTML][HTML] Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach
N Garçon, S Morel, A Didierlaurent, D Descamps… - BioDrugs, 2011 - Springer
A novel human papillomavirus (HPV) vaccine has been formulated with virus-like particles of
the L1 protein of HPV-16 and HPV-18, and the Adjuvant System 04 (AS04). AS04 is a …
the L1 protein of HPV-16 and HPV-18, and the Adjuvant System 04 (AS04). AS04 is a …
Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases
A Hviid, H Svanström, NM Scheller… - Journal of internal …, 2018 - Wiley Online Library
Background Since 2006, human papillomavirus (HPV) vaccines have been introduced in
many countries worldwide. Whilst safety studies have been reassuring, focus has been on …
many countries worldwide. Whilst safety studies have been reassuring, focus has been on …
[HTML][HTML] Adverse events following HPV vaccination: 11 years of surveillance in Australia
Background Australia was the first country to implement a fully funded vaccination program
with quadrivalent human papillomavirus vaccine (4vHPV) in 2007, including males from …
with quadrivalent human papillomavirus vaccine (4vHPV) in 2007, including males from …
Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism
NM Scheller, B Pasternak, H Svanström, A Hviid - Jama, 2014 - jamanetwork.com
Methods| Linking individual-level information from Danish national demographic and health
care registers, described in detail elsewhere, 4 we constructed the source population of all …
care registers, described in detail elsewhere, 4 we constructed the source population of all …
Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review
ABSTRACT INTRODUCTION: The vaccination against Humanpapilloma Virus (HPV) is an
effective strategy to prevent high-risk HPV infection and subsequent cervical carcinogenesis …
effective strategy to prevent high-risk HPV infection and subsequent cervical carcinogenesis …